From cell source to clinical-grade therapeutics — through scientific precision, molecular intelligence, and pharmaceutical-grade quality.
Transforming in-depth molecular characterization into clinical translation.
At Bioflirt Labs, technology is not an accessory to research — it is the foundation of therapeutic precision.
We integrate analytical depth, molecular insight, and GMP-aligned production into a unified platform, built around two core technology pillars.
Bioflirt Labs is the first organization in ASEAN to implement the CytoFLEX Nano platform for high-resolution extracellular vesicle characterization.
This nano-scale flow cytometry system enables particle-resolved EV analysis beyond conventional bulk measurement, supporting precise identity validation and subpopulation profiling.
By integrating CytoFLEX Nano into our standardized QA/QC framework, we strengthen analytical depth, batch consistency, and translational reliability.
At Bioflirt Labs, we operate a dedicated MSC culture platform built on rigorous biological standards — ensuring that every MSC lot is thoroughly qualified, characterized, and maintained with precision. Our practices are aligned with ISCT (International Society for Cell & Gene Therapy) guidelines, establishing a scientifically recognized foundation for cell identity, quality, and functional assessment.
Our platform encompasses:
Beyond culture conditions, we define what our MSCs do — not just what they are. Each cell line is evaluated for functional potency and mechanism of actions (MoAs), linking biological behaviors to measurable outcomes:
Potency index development for lot-to-lot consistency
Every MSC lot is subject to a structured quality control panel before release:
| Parameter | Method |
| Cell identity | Flow cytometry — CD73⁺, CD90⁺, CD105⁺ / CD34⁻, CD45⁻, HLA-DR⁻, CD11b⁻ |
| Differentiation potential | Trilineage differentiation (adipogenic, osteogenic, chondrogenic) |
| Cell health & integrity | MilliPlex-based cell health & cytokine panel (Merck) |
| Potency | Immune cell inhibition & cytokine profiling |
| Microbial safety | Sterility testing & mycoplasma testing & molecular testing |
| Endotoxin | LAL (Limulus Amebocyte Lysate) assay |
Each parameter is evaluated against defined acceptance criteria — ensuring only qualified MSC lots proceed.
Most MSC platforms release cells based on identity markers and sterility alone. At Bioflirt Labs, we apply three additional quality layers that directly impact biological performance, clinical safety, and lot-to-lot reliability.
Xeno-Free Culture System
The foundation of quality begins before any QC test is run — it begins with what the cells are grown in. Conventional MSC culture often relies on animal-derived components such as fetal bovine serum (FBS), which introduce uncontrolled biological variability, immunogenic risk, and regulatory concern for clinical use.
At Bioflirt Labs, we culture all MSCs in a xeno-free system using US-FDA certified xenofree supplement — completely free from animal-derived materials.
This matters because:
Xeno-free culture is not just a best practice — it is a prerequisite for responsible clinical translation.
Knowing that a cell expresses the right markers is not enough. Stressed, metabolically compromised, or functionally declining MSCs can pass identity QC — yet deliver substantially reduced therapeutic activity. MilliPlex-based cell health & cytokine panel (Merck) assesses the biological fitness of each lot at the molecular level, ensuring only cells that are truly healthy — not just phenotypically correct — are released.
Knowing what a cell is does not tell you what it does. Immune cell inhibition assays and cytokine profiling directly measure the biological activity of each MSC lot, linking molecular function to mechanism of actions (MoAs). This aligns with regulatory expectations from the FDA and EMA, which require defined functional potency assays as part of cell therapy release criteria — not just phenotypic characterization.
Every MSC lot is released with a Certificate of Analysis (CoA) documenting all QC parameters — providing full transparency, scientific traceability, and confidence for downstream application.
At Bioflirt Labs, we develop extracellular vesicles and exosomes that meet clinical-grade standards — defined by molecular identity, functional potency, and validated manufacturing processes aligned with international regulatory frameworks.
Bioflirt Labs is the first organization in ASEAN to implement the CytoFLEX Nano platform for high-resolution single-particle EV characterization — enabling particle-resolved analysis beyond conventional bulk measurement, integrated within our ISO 13485–aligned QA/QC framework.
Why Single-Particle Characterization — Beyond NTA
Nanoparticle Tracking Analysis (NTA) measures the average behavior of millions of particles at once. It tells you how many — but not what they are. Single-particle analysis using CytoFLEX Nano resolves each vesicle individually, enabling:
NTA gives you a count. CytoFLEX Nano gives you a fingerprint.
A single analytical lens cannot capture the full biological complexity of an exosome. Multi-OMICs integration builds a complete molecular portrait — connecting surface identity to internal cargo to functional pathway activity.
Where others report particle concentration and one or two surface markers, we deliver mechanism-informed molecular signatures — batch by batch.
Characterization tells you what an exosome contains. Potency testing tells you whether it actually works and how. At Bioflirt Labs, potency is a structured framework linking molecular cargo to defined biological outcomes:
Each potency parameter is mapped back to a defined MoA — creating a potency-to-mechanism index that supports indication-specific development and regulatory documentation.
We don’t just show that our exosomes are active. We show what they do, how they do it, and why it matters clinically.
Particle concentration alone does not define therapeutic relevance. Two EV preparations may contain comparable particle numbers — yet differ significantly in molecular cargo, mechanism of action, and clinical potential.
At Bioflirt Labs, therapeutic value is defined through molecular identity, mechanism-linked profiling, and validated functional performance.
Because in therapeutic exosomes — quality is not measured by how many — but by what they carry and how they function.
At Bioflirt Labs, quality assurance is not a final checkpoint — it is embedded into every stage of development, characterization, and manufacturing. Our QA/QC framework is designed to meet the expectations of both regulatory agencies and clinical environments, reflecting the rigor required for advanced biologics and cell therapy products.
Regulatory Alignment
Our systems are structured in alignment with internationally recognized standards governing the production of biologics, cell therapies, and medical devices:
MISEV2023 — Ensuring our EV analytical methods reflect the highest current international scientific consensus
Every product lot undergoes safety testing aligned with pharmacopeial standards applicable to injectable biologics and cell therapy products:
Molecular Impurity Screening — Detection of residual process-related impurities affecting safety or potency
Quality must be built in — not inspected in. This means Critical Quality Attributes (CQAs) are defined before manufacturing begins, process parameters are validated against acceptance criteria, and every batch is released with a full Certificate of Analysis (CoA) for end-to-end traceability.
The quality of a therapeutic product is inseparable from the instruments used to produce it. At Bioflirt Labs, our manufacturing infrastructure is equipped exclusively with Thermo Scientific Cell Therapy Series (CST)-certified instruments — a designation developed specifically for clinical-grade cell therapy and advanced biologic manufacturing.
CST certification is not simply a product quality mark. It signifies that each instrument has been designed, validated, and documented to meet the operational requirements of Advanced Therapy Medicinal Products (ATMPs) — the regulatory category governing cell therapies, gene therapies, and tissue-engineered products under EMA and equivalent international frameworks.
This means every piece of equipment in our production environment contributes to a traceable, auditable, and reproducible manufacturing chain — one that aligns with GMP expectations for ATMPs from day one of production. All instruments are maintained under a defined calibration and preventive maintenance schedule, fully documented within our quality management system.
When the instruments are certified for ATMPs, the manufacturing chain earns the same standard.
While most platforms stop at identity and sterility, Bioflirt Labs integrates cell health assessment and functional potency testing as core release criteria — not optional add-ons.
We don’t just culture cells — we define their identity, their function, and their therapeutic relevance.
From single-particle precision to mechanism-defined potency,
